Skip to main content
Canna~Fangled Abstracts

Cannabidiol reduces withdrawal symptoms in nicotine-dependent rats

By April 29, 2021No Comments
. 2021 Apr 28.

doi: 10.1007/s00213-021-05845-4.

Online ahead of print.
Lauren C Smith 1 2, Lani Tieu 2, Raymond T Suhandynata 3, Brent Boomhower 2, Melissa Hoffman 3, Yadira Sepulveda 4, Lieselot L G Carrette 2, Jeremiah D Momper 4, Robert L Fitzgerald 3, Kate Hanham 5, Joseph Dowling 5, Marsida Kallupi 6 7, Olivier George 8 9
Affiliations 

Abstract

Rationale: Cannabidiol (CBD) reduces craving in animal models of alcohol and cocaine use and is known to modulate nicotinic receptor function, suggesting that it may alleviate symptoms of nicotine withdrawal. However, preclinical evaluation of its efficacy is still lacking.

Objectives: The goal of this study was to test the preclinical efficacy of a chronic CBD treatment in reducing nicotine dependence using measures of withdrawal symptoms including somatic signs, hyperalgesia, and weight gain during acute and protracted abstinence.

Methods: Male and female Wistar rats were made dependent on nicotine using osmotic minipumps (3.15 mg/kg/day) for 2 weeks, after which minipumps were removed to induce spontaneous withdrawal. Three groups received CBD injections at doses of 7.5, 15, and 30 mg/kg/day for 2 weeks, starting 1 week into chronic nicotine infusion. The control groups included rats with nicotine minipumps that received vehicle injections of sesame oil instead of CBD; rats implanted with saline minipumps received sesame oil injections (double vehicle) or the highest dose of CBD 30 mg/kg/day. Throughout the experiment, serum was collected for determination of CBD and nicotine concentrations, mechanical sensitivity threshold and withdrawal scores were measured, and body weight was recorded.

Results: CBD prevented rats from exhibiting somatic signs of withdrawal and hyperalgesia during acute and protracted abstinence. There was no dose-response observed for CBD, suggesting a ceiling effect at the doses used and the potential for lower effective doses of CBD. The saline minipump group did not show either somatic signs of withdrawal or hyperalgesia during acute and protracted abstinence, and the highest dose of CBD used (30 mg/kg/day) did not alter these results.

Conclusions: This preclinical study suggests that using CBD as a strategy to alleviate the withdrawal symptoms upon nicotine cessation may be beneficial.

Keywords: Abstinence, Addiction, CBD, Tobacco, Treatment, Withdrawal

References

    1. (2018) Cannabidiol (Epidiolex) for epilepsy. Med Lett Drugs Ther 60(1559): 182–184
    1. Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M, Pertwee RG, Castillo AI, Romero J, Martinez-Orgado J (2008) Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res 64(6):653–658 – PubMed – DOI – PMC
    1. Anderson GD, Chan LN (2016) Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet 55(11):1353–1368 – PubMed – DOI – PMC
    1. Bagdas D, Alkhlaif Y, Jackson A, Carroll FI, Ditre JW, Damaj MI (2018) New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 138:72–79 – PubMed – PMC – DOI
    1. Carstens E, Anderson KA, Simons CT, Carstens MI, Jinks SL (2001) Analgesia induced by chronic nicotinne infusion in rats: differences by gender and pain test. Psychopharmacology 157(1):40–45 – PubMed – DOI – PMC

Leave a Reply